Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H6N2O |
Molecular Weight | 74.0818 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC(N)=O
InChI
InChIKey=BEBCJVAWIBVWNZ-UHFFFAOYSA-N
InChI=1S/C2H6N2O/c3-1-2(4)5/h1,3H2,(H2,4,5)
Molecular Formula | C2H6N2O |
Molecular Weight | 74.0818 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Preparation of Fab' from murine IgG2a for thiol reactive conjugation. | 2001 |
|
Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. | 2001 Dec |
|
Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa. | 2001 Jun |
|
A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. | 2001 Mar 1 |
|
Pemetrexed disodium (Eli Lilly). | 2001 Nov |
|
Proton transfer dynamics of GART: the pH-dependent catalytic mechanism examined by electrostatic calculations. | 2001 Nov |
|
Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase. | 2001 Nov 13 |
|
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. | 2001 Sep 1 |
|
Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. | 2001 Sep-Oct |
|
10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway. | 2002 Aug |
|
The pemetrexed/gemcitabine combination in pancreatic cancer. | 2002 Aug 15 |
|
Pemetrexed safety and dosing strategy. | 2002 Dec |
|
Molecular, biochemical, and cellular pharmacology of pemetrexed. | 2002 Dec |
|
Crystal structures of human GAR Tfase at low and high pH and with substrate beta-GAR. | 2002 Dec 3 |
|
Biochemical and structural characterization of the cross-linked complex of nitrogenase: comparison to the ADP-AlF4(-)-stabilized structure. | 2002 Dec 31 |
|
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. | 2002 Jan 7 |
|
Synthesis of a new antischistosomally active and toxicologically tolerant C-12 monothione surrogate of the universal antihelmintic praziquantel. | 2002 Jul-Aug |
|
Pemetrexed: translational research in breast cancer. | 2002 Jun |
|
PurT-encoded glycinamide ribonucleotide transformylase. Accommodation of adenosine nucleotide analogs within the active site. | 2002 Jun 28 |
|
New N(3)S donor ligand small peptide analogues of the N-mercaptoacetyl-glycylglycylglycine ligand in the clinically used Tc-99m renal imaging agent: evidence for unusual amide oxygen coordination by two new ligands. | 2002 Jun 3 |
|
Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. | 2002 Oct |
|
Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type. | 2002 Oct |
|
Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. | 2002 Sep 15 |
|
Chemically modified "polar patch" mutants of subtilisin in peptide synthesis with remarkably broad substrate acceptance: designing combinatorial biocatalysts. | 2002 Sep 16 |
|
Practical asymmetric synthesis of vicinal diamines through the catalytic highly enantioselective alkylation of glycine amide derivatives. | 2003 |
|
Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells. | 2003 Aug |
|
Tomoregulin ectodomain shedding by proinflammatory cytokines. | 2003 Aug 15 |
|
A defect in the p53 response pathway induced by de novo purine synthesis inhibition. | 2003 Dec 5 |
|
Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene and derived amino acid amides. | 2003 Feb 13 |
|
LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis. | 2003 Nov-Dec |
|
10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase. | 2003 Oct 1 |
|
FDA drug approval summaries: pemetrexed (Alimta). | 2004 |
|
The crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase: mechanism of hydrolysis and its interplay with the dehydrogenase domain. | 2004 Apr 2 |
|
BMS-201620: a selective beta 3 agonist. | 2004 Jul 5 |
|
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. | 2004 Jun 15 |
|
Basal jawed vertebrate phylogeny inferred from multiple nuclear DNA-coded genes. | 2004 Mar 11 |
|
Kinetic and mechanistic investigation of the selective acidolysis of the C-terminal amide bond of N-acyl-N,alpha,alpha-trialkyl glycine amides. | 2005 Jul |
|
Application of intramolecular 1,3-dipolar cyclic addition of azide and olefin; construction of (pyrrolidine-2-ylidene)glycinate and glycinamides. | 2005 May |
|
Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. | 2005 May 16 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 01:25:14 UTC 2023
by
admin
on
Thu Jul 06 01:25:14 UTC 2023
|
Record UNII |
4JDT453NWO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
598-41-4
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
42843
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
DTXSID1060508
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
DB03636
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
209-932-4
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
4JDT453NWO
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
Glycinamide
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
69020
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY | |||
|
C018556
Created by
admin on Thu Jul 06 01:25:14 UTC 2023 , Edited by admin on Thu Jul 06 01:25:14 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
|